Addressing Dementia Via Agitation-Centered Evaluation
Trial details
- Registry ID
- NCT03226522
- Phase
- Phase 2, Phase 3
Drug identity checked against registry records
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Addressing Dementia Via Agitation-Centered EvaluationNCT03226522 | AXSM | Phase 2, Phase 3 | Completed | 2020-04-17Actual |
| A Study to Assess the Efficacy and Safety of AXS-05 in Subjects With Alzheimer's Disease AgitationNCT05557409 | AXSM | Phase 3 | Completed | 2024-11-21Actual |
| Assessing Clinical Outcomes in Alzheimer's Disease AgitationNCT04797715 | AXSM | Phase 3 | Completed | 2022-11-21Actual |
| No regulatory events match this view.This does not mean no FDA events have occurred. |